Skip to main content
Equibles
GLSI logo

GLSI · Greenwich LifeSciences, Inc. · Documents

Track GLSI — free

Use GLSI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLSI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.28 -0.81 (-5.03%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed Aug 11, 2026
Market Cap
$224.28M
Shares
14.68M
Volume · Nov 12 207.01K Avg daily vol (3M) 129.33K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $19.36M 10-K filed Jun 1, 2026 Quarterly report FY2026 Q2 Net loss $3.95M 10-Q filed Aug 11, 2026
2026
Oct 26
Annual report to holders ARS
Annual report to holders

Greenwich LifeSciences is enrolling patients in Phase III Flamingo-01, evaluating GLSI-100 to prevent breast cancer recurrence, and expanding into Europe with plans for up to 150 sites globally. It needs significant additional financing for operations and product development.

Read from the first part of this long document
Oct 26
Proxy statement DEF 14A
Proxy statement

Greenwich LifeSciences, Inc. will ask stockholders on December 18, 2026 to elect five (5) directors, ratify MaloneBailey LLP for the fiscal year ending December 31, 2026, approve advisory executive compensation, and choose future advisory-vote frequency.

Read from the first part of this long document
Jun 1
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $19.36M Diluted EPS -$1.43
2025
2024
2023
2022
Showing 1–50 of 91 documents
Key facts CIK 1799788 CUSIP 396879108 13F (30d) 56 filings 30 filers Visit website Investor relations